This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by DeSousa, E. A. Articles by Kalman, B. Search for Related Content PubMed PubMed Citation Articles by DeSousa, E. A. Articles by Kalman, B. Social Bookmarking                         What's this?

Cognitive impairments in multiple sclerosis: A review

Department of Neurology, MCP Hahnemann University, Philadelphia, Pennsylvania.

Ross H. Albert, BA

Department of Biochemistry, MCP Hahnemann University, Philadelphia, Pennsylvania.

Bernadette Kalman, MD, PhD

Department of Neurology, MCP Hahnemann University, Philadelphia, Pennsylvania.

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). Cognitive impairment (CI) may develop at any time during the course of the disease in the presence or absence of neurological disability. On the basis of comprehensive neuropsychological studies, there is now a consensus among investigators that 45 percent to 65 percent of MS patients suffer from some degree and form of cognitive difficulty. Features of CI include bradyphrenia; impaired attention, concentration and abstract reasoning; reduced manual speed and dexterity; deficits in memory retrieval; and language deficits in both the relapsingremitting and progressive forms of MS. Impairments in all cognitive domains may result from the diffuse spread of microscopic pathology, although a preferential lobar distribution of plaques can present with a predominant deficit in the corresponding cognitive function. Nevertheless, the severity of CI best correlates with total microscopic and macroscopic disease burden of the brain as defined by recently developed magnetic resonance imaging (MRI) sequences. A disruption of connecting intercortical and subcortical pathways is likely to be the main cause of metabolic and functional abnormalities in neurons. However, a direct toxic effect of soluble inflammatory products may also compromise neuronal function and survival. Early treatment of MS with interferons and copaxone can prevent or delay the onset of both neurological and cognitive disabilities by reducing the inflammatory activity and damage in the CNS. Until more powerful neuroprotective agents become available, simple neuropsychological screening and cognitive rehabilitation for memory and language impairments will remain important components in the care of MS patients.

Key Words: multiple sclerosis • cognitive impairments • neuropathology • neuroimaging

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 17, No. 1, 23-29 (2002)
DOI: 10.1177/153331750201700104


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M Ukkonen, T Vahvelainen, P Hamalainen, P Dastidar, and I Elovaara Cognitive dysfunction in primary progressive multiple sclerosis: a neuropsychological and MRI study Multiple Sclerosis, September 1, 2009; 15(9): 1055 - 1061. [Abstract] [PDF]

				A. A. Argyriou and N. Makris Review Article: Multiple Sclerosis and Reproductive Risks in Women Reproductive Sciences, October 1, 2008; 15(8): 755 - 764. [Abstract] [PDF]

				N Figved, R Benedict, G Klevan, K. Myhr, H. Nyland, N. Landro, J. Larsen, and D Aarsland Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis Multiple Sclerosis, September 1, 2008; 14(8): 1084 - 1090. [Abstract] [PDF]

				M. Younes, J. Hill, J. Quinless, M. Kilduff, B. Peng, S. Cook, and D. Cadavid Internet-based cognitive testing in multiple sclerosis Multiple Sclerosis, September 1, 2007; 13(8): 1011 - 1019. [Abstract] [PDF]

				E L Sampson, J D Warren, and M N Rossor Young onset dementia Postgrad. Med. J., March 1, 2004; 80(941): 125 - 139. [Abstract] [Full Text] [PDF]

				M. Gadea, M. C. Martinez-Bisbal, L. Marti-Bonmati, R. Espert, B. Casanova, F. Coret, and B. Celda Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis Brain, January 1, 2004; 127(1): 89 - 98. [Abstract] [Full Text] [PDF]

				K. Hawker, E. Frohman, and M. Racke Levetiracetam for Phasic Spasticity in Multiple Sclerosis Arch Neurol, December 1, 2003; 60(12): 1772 - 1774. [Abstract] [Full Text] [PDF]

				C Sfagos, C C Papageorgiou, K K Kosma, E Kodopadelis, N K Uzunoglu, D Vassilopoulos, and A D Rabavilas Working memory deficits in multiple sclerosis: a controlled study with auditory P600 correlates J. Neurol. Neurosurg. Psychiatry, September 1, 2003; 74(9): 1231 - 1235. [Abstract] [Full Text] [PDF]